公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL) | Park K.; Kim J.-H.; Cho E.K.; Kang J.-H.; JIN-YUAN SHIH ; Zimmermann A.H.; Lee P.; Alexandris E.; Puri T.; Orlando M. | Cancer Research and Treatment | 19 | 15 |